{"schema_version":"secwatch.filing_event.v1","accession":"0000105770-23-000043","form_type":"8-K","ticker":"WST","cik":"0000105770","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2023-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.038771+00:00","generated_at":"2026-06-12T23:39:12.251536+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"West Pharma Q2 net sales $753.8M (-2.3%), adjusted EPS $2.11; raises FY2023 guidance","bullets":["Reported Q2 diluted EPS of $2.06; adjusted diluted EPS of $2.11, down from $2.47 YoY.","Net sales declined 2.3% to $753.8M; organic net sales fell 2.5%.","Proprietary Products segment sales down 5.5% to $618.0M, driven by COVID-19 related decline; base business grew double digits.","Contract-Manufactured Products segment sales up 15.3% to $135.8M, led by injection-device components.","FY2023 net sales guidance raised to $2.970-2.995B; adjusted EPS guidance raised to $7.65-7.80."],"urls":{"canonical":"https://secwatch.observer/filing/0000105770-23-000043","json":"https://secwatch.observer/filing/0000105770-23-000043.json","markdown":"https://secwatch.observer/filing/0000105770-23-000043.md","text":"https://secwatch.observer/filing/0000105770-23-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000043/0000105770-23-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000043/wst-20230727.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T23:39:12.251536+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ed1ea59a8d23905a281c64dd63f24722c09c998c","claim":"WEST PHARMACEUTICAL SERVICES INC reported second-quarter 2023 results: revenue $753.8 million, EPS $2.06. Guidance raised.","evidence_excerpt":"West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2023 and updated full-year 2023 financial guidance. Second-Quarter 2023 Summary (comparisons to prior-year period) • Net sales of $753.8 million declined 2.3%; organic net sales declined 2.5%. • Reported-diluted EPS of $2.06, compared to $2.48 in the same period last year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000043/0000105770-23-000043-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second-quarter 2023"},{"label":"Revenue","value":"$753.8 million"},{"label":"EPS","value":"$2.06"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}